HOME > NATION > Article

Text Size

small

medium

large


U.S. FDA OKs Alzheimer's Remedy by Eisai, Biogen

U.S. FDA OKs Alzheimer's Remedy by Eisai, Biogen

   New York, June 7 (Jiji Press)--The U.S. Food and Drug Administration on Monday approved a remedy for Alzheimer's disease developed jointly by Japan's Eisai Co. <4523> and U.S. biopharmaceutical company Biogen Inc.
   The drug, aducanumab, became the world's first approved drug that directly works on substances that cause Alzheimer's disease. All previous drugs only temporarily delay the progression of the disease.
   Hopes are high for the drug as there are worries over a spike in Alzheimer's patients amid the aging of the society.
   The FDA said that it gave the approval after clinical tests showed the use of the drug led to a consistent decrease in the amount of amyloid beta plaques, which can trigger Alzheimer's disease when they are accumulated in patients' brains.
   Meanwhile, some experts are casting doubt on the results of the clinical tests showing aducanumab's ability to restrain cognitive decline.

To read a full story, please click here to find out how to subscribe.

NATION

Aomori Tourism Information

HEADLINES

POLITICS
Leading Opposition CDP to Downgrade Consumption Tax Cut Pledge to "Target"
ECONOMY
Japan Starts Minting New 500-Yen Coins
SPORTS
10,000-Spectator Ceiling Set for Tokyo Games
OTHER
Woman Referred to Prosecutors for Insulting TV Personality Chiemi Hori Online

AFP-JIJI PRESS NEWS JOURNAL


Photos